{"disease":{"id":"pediculosis-capitis","name":"Pediculosis capitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":10,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"abametapir","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeglyze","generic_name":"ABAMETAPIR","company_name":"Hatchtech","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 5","drug_class":"","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"tetramethrin","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phthalthrin","generic_name":"TETRAMETHRIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"tetramethrin","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"permethrin","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elimite","generic_name":"PERMETHRIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrethroid [EPC]","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"lignocaine","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lignocaine","company_name":"University of Malaya","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lidocaine-hydrochloride","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lignospan Forte","generic_name":"Lidocaine Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"neuronal membrane ionic channels","drug_class":"local anesthetic, amide type","quality_score":68,"revenue":null,"mechanism":"Lidocaine stabilizes neuronal membrane by inhibiting ionic fluxes required for impulse initiation and conduction."},{"drug_id":"spinosad","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Natroba","generic_name":"SPINOSAD","company_name":"Cipher","drug_phase":"marketed","molecular_target":"","drug_class":"Pediculicide [EPC]","quality_score":40,"revenue":null,"mechanism":"Natroba works by activating glutamate-gated chloride channels in the nervous system of lice, leading to an influx of chloride ions and eventual death."},{"drug_id":"malathion","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ovide","generic_name":"MALATHION","company_name":"Taro","drug_phase":"marketed","molecular_target":"Melatonin receptor type 1A","drug_class":"Cholinesterase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pyrethrins","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pyrethrins","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lidocain","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lidocain","company_name":"Bayer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xylocain","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"xylocain","company_name":"Saint-Joseph University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":10,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05378477","title":"A Clinical Trial to Evaluate Efficacy and Safety of a New Suffocating Head Lice Product.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":220,"lead_sponsor_name":"Oystershell NV","has_results":false},{"nct_id":"NCT03286101","title":"Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"United Laboratories","has_results":false},{"nct_id":"NCT03617926","title":"A Clinical Trial to Evaluate Efficacy and Safety of a Water-soluble Head Lice Product.","phase":"NA","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Oystershell NV","has_results":true},{"nct_id":"NCT05565820","title":"A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Alliance Pharmaceuticals","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}